eMedicine Specialties > Neurology > Neuro-oncology

Pituitary Tumors: Multimedia

Author: Jorge Kattah, MD, Head, Program Director, Professor, Department of Neurology, University of Illinois College of Medicine at Peoria
Contributor Information and Disclosures

Updated: Jan 14, 2009

Multimedia

This is a characteristic bitemporal hemianopic vi...
(Enlarge Image)
Media file 1: This is a characteristic bitemporal hemianopic visual field defect.
[ CLOSE WINDOW ]
This is a characteristic bitemporal hemianopic vi...

This is a characteristic bitemporal hemianopic visual field defect.

This contrast-enhanced coronal MRI was obtained i...
(Enlarge Image)
Media file 2: This contrast-enhanced coronal MRI was obtained in a patient who complained of visual loss.
[ CLOSE WINDOW ]
This contrast-enhanced coronal MRI was obtained i...

This contrast-enhanced coronal MRI was obtained in a patient who complained of visual loss.

This visual field was plotted using a Goldman per...
(Enlarge Image)
Media file 3: This visual field was plotted using a Goldman perimeter (ie, kinetic perimetry). It was obtained from a patient who reported visual loss and had a normal endocrine workup. The dark areas correspond to the impaired peripheral visual field. This visual field defect is consistent with an intrasellar lesion.
[ CLOSE WINDOW ]
This visual field was plotted using a Goldman per...

This visual field was plotted using a Goldman perimeter (ie, kinetic perimetry). It was obtained from a patient who reported visual loss and had a normal endocrine workup. The dark areas correspond to the impaired peripheral visual field. This visual field defect is consistent with an intrasellar lesion.

Coronal T1 precontrast MRI A (left panel), B post...
(Enlarge Image)
Media file 4: Coronal T1 precontrast MRI A (left panel), B postcontrast (middle panel) and T2 (right panel) showing a sellar mass causing obvious left and upward displacement of the optic chiasm. The mass is a histologically proven pituitary macroadenoma, which presented initially with a large cystic subfrontal extension that was successfully resected in April of 2006. This patient has been observed closely for 2.5 years and despite obvious mass effect, he has no visual complaints and the neuro-ophthalmologic evaluation is normal. Although infrequent, clinicians should be aware of this possibility. Close follow-up is required.
[ CLOSE WINDOW ]
Coronal T1 precontrast MRI A (left panel), B post...

Coronal T1 precontrast MRI A (left panel), B postcontrast (middle panel) and T2 (right panel) showing a sellar mass causing obvious left and upward displacement of the optic chiasm. The mass is a histologically proven pituitary macroadenoma, which presented initially with a large cystic subfrontal extension that was successfully resected in April of 2006. This patient has been observed closely for 2.5 years and despite obvious mass effect, he has no visual complaints and the neuro-ophthalmologic evaluation is normal. Although infrequent, clinicians should be aware of this possibility. Close follow-up is required.

More on Pituitary Tumors

Overview: Pituitary Tumors
Differential Diagnoses & Workup: Pituitary Tumors
Treatment & Medication: Pituitary Tumors
Follow-up: Pituitary Tumors
Multimedia: Pituitary Tumors
References
[ CLOSE WINDOW ]

References

  1. Vlotides G, Eigler T, Melmed S. Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. Endocr Rev. Apr 2007;28(2):165-86. [Medline].

  2. Talkad AV, Kattah JC, Xu MY, et al. Prolactinoma presenting as painful postganglionic Horner syndrome. Neurology. Apr 27 2004;62(8):1440-1. [Medline].

  3. Semple PL, Webb MK, de Villiers JC, Laws ER Jr. Pituitary apoplexy. Neurosurgery. 2005;56(1):65-72; discussion 72-3. [Medline].

  4. Biousse V, Newman NJ, Oyesiku NM. Precipitating factors in pituitary apoplexy. J Neurol Neurosurg Psychiatry. Oct 2001;71(4):542-5. [Medline].

  5. Gnanalingham KK, Bhattacharjee S, Pennington R, et al. The time course of visual field recovery following transphenoidal surgery for pituitary adenomas: predictive factors for a good outcome. J Neurol Neurosurg Psychiatry. Mar 2005;76(3):415-9. [Medline].

  6. Alameda C, Lucas T, Pineda E, et al. Experience in management of 51 non-functioning pituitary adenomas: indications for post-operative radiotherapy. J Endocrinol Invest. Jan 2005;28(1):18-22. [Medline].

  7. Colin P, Jovenin N, Delemer B, et al. Treatment of pituitary adenomas by fractionated stereotactic radiotherapy: a prospective study of 110 patients. Int J Radiat Oncol Biol Phys. Jun 1 2005;62(2):333-41. [Medline].

  8. Conomy JP, Ferguson JH, Brodkey JS, Mitsumoto H. Spontaneous infarction in pituitary tumors: neurologic and therapeutic aspects. Neurology. Jun 1975;25(6):580-7. [Medline].

  9. David, NJ, Gargano FP, Glaser JS. Pituitary apoplexy in clinical perspective. In: Neurophthalmology Symposium. Vol 8. St Louis: CV Mosby; 1975:140-165.

  10. Dawson BH, Kothandaram P. Acute massive infarction of pituitary adenomas. A study of five patients. J Neurosurg. Sep 1972;37(3):275-9. [Medline].

  11. Gharib H, Frey HM, Laws ER, et al. Coexistent primary empty sella syndrome and hyperprolactinemia. Report of 11 cases. Arch Intern Med. Jul 1983;143(7):1383-6. [Medline].

  12. Greenberg HS, Chandler WF, Ensminger WD. Radiosensitization with carotid intra-arterial bromodeoxyuridine +/- 5-fluorouracil biomodulation for malignant gliomas. Neurology. Sep 1994;44(9):1715-20. [Medline].

  13. Jho HD. Endoscopic endonasal pituitary surgery: Technical aspects. Contemporary Neurosurgery. 1997;19:1-8.

  14. Jho HD, Carrau RL, Ko Y, Daly MA. Endoscopic pituitary surgery: an early experience. Surg Neurol. Mar 1997;47(3):213-22; discussion 222-3. [Medline].

  15. Levy A, Lightman SL. Diagnosis and management of pituitary tumours. BMJ. Apr 23 1994;308(6936):1087-91. [Medline].

  16. Melmed S. Acromegaly. N Engl J Med. Apr 5 1990;322(14):966-77. [Medline].

  17. Molitch ME. Pregnancy and the hyperprolactinemic woman. N Engl J Med. May 23 1985;312(21):1364-70. [Medline].

  18. Oldfield EH, Doppman JL, Nieman LK, Chrousos GP, Miller DL, Katz DA, et al. Petrosal sinus sampling with and without corticotropin-releasing hormone for the differential diagnosis of Cushing's syndrome. N Engl J Med. Sep 26 1991;325(13):897-905. [Medline].

  19. Orth DN. Cushing's syndrome. N Engl J Med. Mar 23 1995;332(12):791-803. [Medline].

  20. Thorner MO, Vance ML, Laws ER. The anterior pituitary. In: Williams, ed. Textbook of Endocrinology. Philadelphia: WB Saunders; 1998:249-340.

  21. Zhang X, Horwitz GA, Heaney AP, Nakashima M, Prezant TR, Bronstein MD, et al. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab. Feb 1999;84(2):761-7. [Medline].

[ CLOSE WINDOW ]

Further Reading

[ CLOSE WINDOW ]

Keywords

pituitary adenoma, pituitary tumor, hormone deficiencies, hormone overproduction, prolactinoma, acromegaly, Cushing disease, Cushing syndrome, hormone therapy, pituitary mass

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

Jorge Kattah, MD, Head, Program Director, Professor, Department of Neurology, University of Illinois College of Medicine at Peoria
Jorge Kattah, MD is a member of the following medical societies: American Academy of Neurology, American Neurological Association, and New York Academy of Sciences
Disclosure: Biogen Honoraria Consulting; Bayer Corporation Honoraria Consulting

Medical Editor

Frederick M Vincent Sr, MD, Clinical Professor, Department of Neurology and Ophthalmology, Michigan State University Colleges of Human and Osteopathic Medicine
Frederick M Vincent Sr, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, American College of Forensic Examiners, American College of Legal Medicine, American College of Physicians, and Michigan State Medical Society
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Robert A Egan, MD, Director of Neuro-Ophthalmology, St Helena Hospital
Robert A Egan, MD is a member of the following medical societies: American Academy of Neurology, American Heart Association, North American Neuro-Ophthalmology Society, and Oregon Medical Association
Disclosure: Nothing to disclose.

CME Editor

Matthew J Baker, MD, Consulting Staff, Collier Neurologic Specialists, Naples Community Hospital
Matthew J Baker, MD is a member of the following medical societies: American Academy of Neurology
Disclosure: Nothing to disclose.

Chief Editor

Robert A Egan, MD, Director of Neuro-Ophthalmology, St Helena Hospital
Robert A Egan, MD is a member of the following medical societies: American Academy of Neurology, American Heart Association, North American Neuro-Ophthalmology Society, and Oregon Medical Association
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.